Floatz logo

Rhil-7

Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Medical College of WisconsinPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Primary Mediastinal Large B-cell Lymphoma (PMBCL) cohort.

Asset / SponsorPhaseRating
Epirubicin
Seda S. Tolu
Phase 2BB
Pembrolizumab
Seda S. Tolu
Phase 2BB
Wztl-002 Car T-Cells
Malaghan Institute of Medical Research
Phase 2CCC
tc011
TICAROS Co., Ltd.
Phase 1/2CC
VNX-101
Vironexis Biotherapeutics Inc.
Phase 1/2CC

View all 13 →

Same molecule, other indications

Rhil-7 is also rated in:

B-cell non-Hodgkin lymphomaDormant
B
Indicative ·
62 / 100
View asset →
Lymphoma, Non-hodgkinsDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →